BRIEF-Antibe Therapeutics announces enrollment of first subjects in Phase 2B GI safety study for lead drug, ATB-346
September 08, 2017 at 07:14 AM EDT
* Antibe Therapeutics Inc - enrollment commenced for key phase 2B GI safety study for ATB-346, remain on previously announced schedule Source text for Eikon: Further company coverage:
